drugset / Trial / NCT04743791

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

NCT04743791

Phase 4 Recruiting 30 enrolled Sally E. Wenzel MD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.

Timeline

Start
2022-10-17
Primary completion
2026-07
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dupilumab Monoclonal antibody 200 mg Subcutaneous

Indications